HS 20090
Alternative Names: HS-20090; Recombinant human anti-RANKL monoclonal antibodyLatest Information Update: 01 Sep 2023
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action RANK ligand modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bone metastases
Most Recent Events
- 20 Apr 2023 Phase-I clinical trials in Bone metastases (Prevention) in China (SC) (NCT05777109)
- 21 Mar 2023 Jiangsu Hansoh Pharmaceutical plans a phase I trial for Bone metastatis (Prevention) in China in April 2023 (SC) (NCT05777109)
- 30 Jun 2021 Jiangsu Hansoh Pharmaceutical plans a phase I trial Bone metastases (Prevention) (SC, Injection) (NCT04940845)